Affymax Largely Ducks Investor Suit Over Anemia Drug
A California federal judge on Tuesday trimmed a putative shareholder class action claiming Affymax Inc. and four executives misled investors about safety issues with anemia drug Omontys, ruling the plaintiffs hadn't shown most...To view the full article, register now.
Already a subscriber? Click here to view full article